Inhibition of Growth Hormone Receptor Activation by Pegvisomant may Increase Bone Density in Acromegaly

Treatment of acromegaly with pegvisomant lowers serum IGF-1 and raises serum growth hormone. As both IGF-1 and GH are important for bone growth and remodeling, we were concerned that lowering of IGF-1 could cause loss of bone. To evaluate the effects of treatment of acromegaly with pegvisomant on bone mineral density (BMD) we developed an observational, prospective study. 7 acromegaly patients participated in the study. Male and female subjects aged 18 years or more were eligible to participate. Patients were eugonadal or on adequate gonadal replacement therapy for at least 3 years before participating in the study. These patients were treated with a mean dosage of 20 mg of pegvisomant daily for up to 7 years. Bone mineral density (BMD) was evaluated by dual X-ray absorbtiometry (DXA) at baseline, 8, and 18 months as a part of a prospective trial and periodically thereafter. Baseline mean serum insulin-like growth factor-1 (IGF-1) concentration +/- SD was elevated in all patients (679.86 +/- 138.21 ng/ml). The IGF-1 concentrations at 18 months decreased significantly from baseline (p = 0.016). Wilcoxon signed-rank tests showed significant increases in the spine BMD from baseline to 18 months (p = 0.016) and significant increases in the right hip BMD from baseline to 18 months (p = 0.032). The range of the increases was 4.3-17.8% at 7 years. It is concluded that successful treatment of acromegaly with pegvisomant increases BMD.